Template:NSCLC molecular workup: Difference between revisions
Jump to navigation
Jump to search
m Specified |
+Ref |
||
| Line 1: | Line 1: | ||
{{Edit|Template:NSCLC molecular workup}}<br>For primary lung non-small cell carcinoma (NSCLC) stages IB - IV (such as being more than 3 cm in size), generally perform full next generation sequencing panel (DNA and RNA) with PDL-1 immunostaining. For advanced stage NSCLC that | {{Edit|Template:NSCLC molecular workup}}<br>For primary lung non-small cell carcinoma (NSCLC) stages IB - IV (such as being more than 3 cm in size), generally perform full next generation sequencing panel (DNA and RNA) with PDL-1 immunostaining. For an advanced stage NSCLC that is not a candidate for biopsy or re-biopsy, a viable alternative is “liquid biopsy” on peripheral blood for circulating tumor DNA.<ref>{{cite web|url=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf|title=National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Non-Small Cell Lung Cancer. Version 3.2024. Section: Principles of molecular and biomarker analysis|date=2024-03-12}}</ref> | ||
Latest revision as of 16:05, 15 March 2024
For primary lung non-small cell carcinoma (NSCLC) stages IB - IV (such as being more than 3 cm in size), generally perform full next generation sequencing panel (DNA and RNA) with PDL-1 immunostaining. For an advanced stage NSCLC that is not a candidate for biopsy or re-biopsy, a viable alternative is “liquid biopsy” on peripheral blood for circulating tumor DNA.[1]